Nuwellis, Inc. NUWE

Company to engage clinicians across three key growth markets and highlight the Aquadex SmartFlow® system for precise fluid managementMINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced its participation in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. Across the events, Nuwellis will engage directly

The medical technology company’s growing installed base follows 26% U. S.

Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placementsMINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued commercial momentum for its Aquadex SmartFlow® system, with 31 consoles sold year-to-date in 2026. The Company's year-to-dat

Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product developmentMINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of medical device quality an

One-year anniversary of transition to contract manufacturing highlights gains in margin, quality, supply performance, and cost structure supported by strengthened balance sheet with $8.8 million in cash facilitates disciplined investment in key growth initiativesMINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress under its financial eff

Agreement expands Nuwellis’ pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distributionMINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility Medical, Inc, a cardiac medical technology company, today announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp®

Nuwellis Inc (NUWE) reports strong U.S. growth and improved gross margins while advancing its pediatric label expansion and strategic cardiorenal platform initiatives.

Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026. Second Quarter Results and Recent Highlights: Net sales were $2.0 million in the secon

Expands interoperability, enhances clinician workflow, and establishes the digital foundation for future software-enabled extracorporeal therapiesMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced a digital transformation program designed to position the Aquadex SmartFlow® System as a connected extracorporeal therapy platform for the modern intensive

Veteran medical device engineering leader brings more than 25 years of experience developing and commercializing innovative technologies from concept through market launchMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings more than 25 years of medical device leadership experience i

Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapiesMINNEAPOLIS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced strategic development initiatives to expand the capabilities of its Aquadex SmartFlow® System into a broader extracorporea

Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public OfferingMINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of

Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patientsMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the acceptance of a new single-center retrospective study in Frontiers in Pediatrics, a multi-disciplinary peer-reviewed journ

Entry into Wisconsin’s pediatric critical care market supports the continued growth of Nuwellis' pediatric ultrafiltration platformMINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion into Wisconsin with the installation of its first Aquadex SmartFlow® systems at a leading pediatric healthcare institution. The installation further expands the C

Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report second quarter 2026 financial results on August 13 MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for

Mike McCormick became Nuwellis' new CEO on 30 June and aims to build on the company's positive Q1 2026 performance.

Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalitiesMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a